C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women

Pannacciulli, Nicola; Cantatore, F. P.; Minenna, A; Bellacicco, M; Giorgino, R; Pergola, Giovanni De

doi:10.1038/sj.ijo.0801719

Cited by 180 publications

(111 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the case of CRP, these findings agree with those of several other studies in which high levels of this acute phase reactant -the concentration of which in serum is o3 mg/l in 90% of apparently healthy individuals (Pepys, 1996) -have been associated with insulin resistance, MS, MS components (hypertension, dyslipidaemia, etc.) or diabetes (Hak et al, 1999;Yudkin et al, 1999;Festa et al, 2000;Frohlich et al, 2000a, b;Pannacciulli et al, 2001;Gourdy et al, 2002;McLaughlin et al, 2002;Ford, 2003). The pathophysiological nature of these associations is unclear, but it has been reported that plasminogen activator inhibitor 1, another inflammatory marker of MS, insulin resistance and diabetes (Festa et al, 2002), is correlated with CRP (Festa et al, 2002) and is promoted by CRP in aortic endothelial cells (Devaraj et al, 2003), and it has been suggested that MS may be the result of a long-term hypersensitive reaction (Pickup and Crook, 1998).…”

Section: Discussionmentioning

confidence: 99%

Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin

et al. 2006

View full text Add to dashboard Cite

Background: Patients with metabolic syndrome (MS) have above-average risk of developing atherosclerosis and cardiovascular disease. Inflammation plays a key role in the development of atherosclerosis. High levels of the acute phase reactants C-reactive protein (CRP) and ferritin have been reported to correlate with various components of MS. Patients and methods: The serum CRP, ferritin, glucose, insulin, triglycerides, HDL-cholesterol and total cholesterol concentrations of 598 obese or overweight patients were determined, together with relevant anthropometric parameters. Insulin resistance was evaluated by the HOMA method. MS was diagnosed using the ATP III criteria. Results: CRP levels were higher among patients with central obesity than in those without (5.8 vs 3.9 mg/l; P ¼ 0.003), and higher among those with fasting plasma glucose concentrations X110 mg/dl than in those with lower concentrations (7.4 vs 4.1 mg/l; P ¼ 0.01). Serum ferritin levels were higher among patients with triglyceride concentrations X150 mg/dl than in those with lower levels (76.8 vs 40.1 ng/ml; Po0.001), and higher among those with fasting plasma glucose concentrations X110 mg/dl than in those with lower concentrations (75.7 vs 41.7 ng/ml; P ¼ 0.005). The number of MS criteria that were satisfied increased with CRP and ferritin levels. Patients with insulin resistance also had higher CRP and ferritin levels than those without, 7.3 vs 4.3 mg/l for CRP (P ¼ 0.032) and 124.5 vs 80.1 ng/ml for ferritin (Po0.001). Conclusions: MS and insulin resistance are associated with elevated serum CRP and ferritin. Evaluation of subclinical chronic inflammation in patients with MS and/or insulin resistance by determination of these markers might aid in their evaluation as candidates for aggressive intervention against cardiovascular risk factors.

show abstract

Section: Discussionmentioning

confidence: 99%

Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Because greater body fat is associated with increased CRP expression [17], we considered whether the elevated concentrations of CRP could be confounded by increased adiposity. However, there were no statistically significant differences in levels of leptin, an adipocyte hormone known to correlate strongly with measures of body fat [18] …”

Section: Leptin Levelsmentioning

confidence: 99%

Expression of C-Reactive Protein and Serum Amyloid A in Early to Late Manifestations of Lyme Disease

Uhde

Ajamian

et al. 2016

Clin Infect Dis.

View full text Add to dashboard Cite

Background. Infection with Borrelia burgdorferi, the causative agent of Lyme disease, triggers host immune responses that affect the clinical outcome and are a source of biomarkers with diagnostic utility. Although adaptive immunity to B. burgdorferi has been extensively characterized, considerably less information is available about the development of innate acute-phase responses in Lyme disease. Our aim in this study was to evaluate the expression of C-reactive protein (CRP) and serum amyloid A (SAA), the prototype acute-phase response proteins, in the context of the varying manifestations associated with Lyme borreliosis.Methods. Circulating concentrations of CRP and SAA in patients with a range of early to late objective manifestations of Lyme disease and in individuals with post-treatment Lyme disease syndrome were compared with those in healthy control groups.Results. CRP and SAA levels were significantly elevated in early localized and early disseminated Lyme disease but not in the later stages of active infection. Levels of CRP, but not SAA, were also found to be significantly increased in patients with antibioticrefractory Lyme arthritis and in those with post-treatment Lyme disease syndrome.Conclusions. These findings indicate that circulating CRP and SAA levels are highest when the concentration of spirochetes is greatest in skin and/or blood and that levels decline after the dissemination of the organism to extracutaneous sites in subsequent stages of infection. The data also suggest that antibiotic-refractory Lyme arthritis and post-treatment Lyme disease syndrome are associated with elevated CRP responses that are driven by inflammatory mechanisms distinct from those in active infection.

show abstract

“…A number of markers of inflammation are positively related to measures of adiposity including BMI, waist circumference and abdominal obesity. [10][11][12] However, in addition, inflammation is associated with CVD and type 2 diabetes risk factors, independent of body mass index (BMI). [13][14][15] Prospective studies have also shown that inflammatory markers are independent predictors of both CVD 16,17 and type 2 diabetes.…”

Section: Introductionmentioning

confidence: 99%

Additive benefits of long-chain n-3 polyunsaturated fatty acids and weight-loss in the management of cardiovascular disease risk in overweight hyperinsulinaemic women

et al. 2006

View full text Add to dashboard Cite

Background: Obesity, inflammation, insulin resistance and cardiovascular disease (CVD) risk are inter-related. Both weight-loss and long-chain n-3 polyunsaturated fatty acids (LC n-3 PUFA) are independently known to reduce metabolic risk, but the combined effects are unclear.Objective: This study examines whether addition of LC n-3 PUFA to a low fat/high carbohydrate weight-loss programme results in greater improvements in inflammation, insulin sensitivity and CVD risk, than weight-loss alone. Design: One hundred and sixteen overweight insulin-resistant women entered a 24-week randomised intervention study. Thirty-nine women were randomised to a weight-loss programme, with LC n-3 PUFA (WLFO), 38 to a weight-loss programme with placebo oil (WLPO), and 39 to receive placebo oil, with no weight-loss programme (control). Results: Ninety-three women completed the study (35 WLFO, 32 WLPO and 26 control), with significant weight-loss in WLFO (10.871.0%) and WLPO (12.471.0%) compared to the control group (Po0.0001). The WLFO, but not WLPO or control group, showed significant increases in adipose tissue LC n-3 PUFA (0.3470.20 vs 0.1770.10 and 0.1670.10 %DHA, Po0.0001). Weight-loss showed significant improvements in insulin sensitivity (Po0.001), lipid profile (triglycerides Po0.05) and inflammation (sialic acid Po0.05). Time * group effects showed significant decreases in triglycerides (Po0.05) and increases in adiponectin (Po0.01) with LC n-3 PUFA, in the WLFO vs WLPO groups. Conclusions: Weight-loss improved risk factors associated with CVD, with some additional benefits of LC n-3 PUFA on triglycerides and adiponectin. Given the current low dietary intake of LC n-3 PUFA, greater attention should be given to increase these fatty acids in the treatment of obesity.

show abstract

C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women

Cited by 180 publications

References 29 publications

Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin

Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin

Expression of C-Reactive Protein and Serum Amyloid A in Early to Late Manifestations of Lyme Disease

Additive benefits of long-chain n-3 polyunsaturated fatty acids and weight-loss in the management of cardiovascular disease risk in overweight hyperinsulinaemic women

Contact Info

Product

Resources

About